Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel
Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan Medical Device Sales and Lease Management, Japan
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan Medical Device Sales and Lease Management, Japan
(Breast Cancer) Ipatasertib + Tecentriq + Paclitaxel
Ipatasertib + Tecentriq + chemotherapy as first-line treatment for triple-negative breast cancer achieves an objective response rate of 73%, unaffected by PD-L1 status and genetic factors.
On April 1, 2019, Roche announced Phase I clinical trial results for oral AKT inhibitor Ipatasertib + Tecentriq + chemotherapy (paclitaxel) at the American Association for Cancer Research conference (AACR 2019).
For previously untreated patients with locally advanced or metastatic triple-negative breast cancer, this study assessed the safety and efficacy of this therapeutic combination. The response rate was unaffected by PD-L1 status, PI3KCA/AKT1/PTEN gene mutations.
Additionally, the most common adverse effects observed in most patients were: diarrhea at 19%, and skin itching and desquamation at 27%.
Based on Phase I clinical trial results, this therapeutic approach demonstrated an objective response rate of 73% in triple-negative breast cancer, showing promising efficacy.
Data Source: https://www.roche.com/media/releases/med-cor-2019-04-01.htm
https://www.roche.com/media/releases/med-cor-2019-04-01.htm
This website uses cookies to understand how you interact with it. Accepting indicates your agreement to our use of cookies. Privacy Policy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5